Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2025
The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2025 would elevate research, data collection, and public and professional education around uterine fibroids. It authorize a coordinated federal effort through the Department of Health and Human Services and the National Institutes of Health to expand fibroid research, improve understanding of how fibroid care is covered under Medicaid and CHIP, and enhance public and professional education about fibroids and their treatment options. The bill emphasizes minority populations—especially Black women—who face higher risk and more severe symptoms, aims to reduce diagnostic delays, and supports the development of less invasive, fertility-friendly treatment options. It would also require a two-year report on federal and state expenditures related to Medicaid/CHIP fibroid treatment. In addition to funding for research, the act directs creation or expansion of a Medicaid/CHIP data research database to track services and expenditures for fibroid treatment, and mandates public and provider-facing information campaigns and dissemination efforts to promote awareness, evidence-based care, and access to non-hysterectomy options.
Key Points
- 1Authorizes $30 million per year for fiscal years 2026–2030 to expand, coordinate, and support uterine fibroid research through the NIH and relevant federal agencies.
- 2Establishes or expands a research database to collect data on fibroid treatment under Medicaid and CHIP, with a report to Congress on federal and state expenditures within two years.
- 3Creates a Public Education Program to inform the public about uterine fibroids, including incidence, minority risk, and available treatment options (including non-hysterectomy therapies).
- 4Requires dissemination of information to health care providers through collaboration with medical societies and health systems to promote evidence-based care and to address minority populations’ needs.
- 5Defines “minority individuals” and places emphasis on addressing disparities in fibroid prevalence, symptom burden, diagnosis, and treatment, particularly among Black women and other minority groups.